Association between Hypoxia Inducible Factor Prolyl Hydoxylase Inhibitor or Erythropoiesis-Stimulating Agents and Cardiovascular Disease: a retrospective cohort study with overlap propensity score weighting

Association between Hypoxia Inducible Factor Prolyl Hydoxylase Inhibitor or Erythropoiesis-Stimulating Agents and Cardiovascular Disease: a retrospective cohort study with overlap propensity score weighting - Association between HIF-PHIs or ESAs and CVD: a retrospective cohort study with overlap propensity score weighting

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050850

Enrollment

5000

Registered

2023-09-01

Start date

2023-08-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal anemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Age >=18 years. -Patients with at least one observation of eGFR < 60 ml/min/1.73 m2 in blood test data -Received HIF-PH inhibitors or ESAs.

Exclusion criteria

Exclusion criteria: Patients without a six-month lookback period before the index date. Patients with a diagnosis of CVD prior to the index date (date of first dose of HIF-PH inhibitor or ESA preparation) (see primary endpoint for definition).

Design outcomes

Primary

Measure	Time frame
The composite outcome of cardiovascular diseases including coronary artery disease (I210-4, I219), stroke (I600-11, I613-6, I619, I629-36, I638-9), heart failure (I500-1, I509, I110), atrial fibrillation (I480-4, I489)	—

Secondary

Measure	Time frame
all cause mortality, artery disease (I210-4, I219), stroke (I600-11, I613-6, I619, I629-36, I638-9), heart failure (I500-1, I509, I110), atrial fibrillation (I480-4, I489)	—

Countries

Japan

Contacts

Public ContactHiroyuki Hashimoto

Graduate School of Medicine and Public Health, Kyoto University Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health

hashimoto.hiroyuki.36w@st.kyoto-u.ac.jp0757539469

Outcome results